



THE PRACTITIONER LE PRATICIEN

The occasional trigger point injection

Robert Minty, MD,
CFPC, FCFP

Assistant Professor, Department of Family Medicine,
Northern Ontario School of
Medicine and McMaster
University, Sioux Lookout,
Ont.

Len Kelly, MD,
M.ClinSci, CFPC, FCFP

Associate Professor, Department of Family Medicine,
Northern Ontario School of
Medicine and McMaster
University, Sioux Lookout,
Ont.

Alana Minty

First Year Pharmacy Student,
University of Toronto,
Toronto, Ont.

Correspondence to:
Dr. Robert Minty, Box 489
Sioux Lookout ON P8T 1A8;
fax 807 757-1771;
rminty@gosiuouxlookout.com

This article has been peer
reviewed.

Tigger points and myofascial pain are common diagnoses. They can occur in any patient, even in those not diagnosed with a chronic condition, such as fibromyalgia or recurrent myofascial pain syndromes. The underlying mechanism for the development of these discrete hyperirritable nodular areas of muscles, first described in 1949,¹ is unknown. The commonly acceptable pathological explanation includes an area of contracted muscle sarcomeres² and irritable muscle end plates.³

Clinicians find patients complaining of musculoskeletal pain that does not fit an accepted neurologic or orthopedic strain pattern. The trigger point will be painful to the touch and compression will illicit a local and referred pain that simulates the patient's discomfort.¹

Needling therapies for pain relief have been used for thousands of years.⁴ Chinese physicians performed dry needling in the seventh century AD. Acupuncture and dry needling did not become of major interest to Europeans until the 1800s.

LITERATURE REVIEW

Although commonly encountered in clinical practice, the literature is scant on this subject. There is a distinction in the literature between tender points (associated with fibromyalgia), which are painful to soft touch, and trigger points, which require more pressure and are often an identified muscle knot.⁵ Such a discussion is beyond the scope of this article. Since fibromyalgia patients often have both tender points (considered less responsive to injections)

and trigger points, a trial of a trigger point injection may be beneficial.²

We searched Medline for myofascial pain syndromes, therapy and trigger point injections. Of the 152 articles we found, there were 3 systematic reviews and 15 somewhat controlled studies. Most were level III evidence. A 2000 Cochrane review⁶ concluded that there was inadequate evidence for or against the use of trigger point injections for the management of low back pain.⁶ We examined the literature beyond this review and found several small studies that compared which agents worked best for injections. However, they did not have enough power to comment on overall efficacy.⁷⁻¹⁰

Most studies use a variety of sterile water, lidocaine or bupivacaine, and there is no clearly superior substance. One author found equivalent results with dry needling when compared with local anesthetic.¹¹ Interestingly, a small crossover study of 10 patients did find that the benefits of successful trigger point injections were reversible with intravenous naran, perhaps indicating a local or regional endorphin response to needling.¹¹

The illustrated self-treatment guide by Davies and Davies, *The Trigger Point Therapy Workbook*, is an excellent resource to physicians and patients.¹² It is clearly written and describes how patients can identify and treat their own regional pain trigger points, often with application of pressure, e.g., leaning against a tennis ball over specific points. The classic, 2-volume, *Myofascial Pain and Dysfunction: The trigger point manual*, is a more extensive medical text on the subject.¹³

PATIENT PRESENTATION

While fully developed fibromyalgia and chronic pain syndromes require interdisciplinary rehabilitation services, primary care physicians may often be faced with a patient with isolated or recurrent trigger points.

Typically, a patient will present with pain or paresthesia symptoms that do not fit an organic illness diagnostic pattern. Rather than feeling overwhelmed at the vast differential diagnosis, one should perform a simple search for trigger points, which very often results in positive findings. An appropriate examination is prudent to rule out serious pathology. This is followed by a simple trigger point injection, which may alleviate the vast majority of the patient's myofascial pain. A common response would be an 8 or 9 out of 10 pain reduction. The neck and shoulder are common sites of myofascial pain (Fig. 1 and Fig. 2).

If the trigger point is not found, the patient may leave with a long series of investigations in front of him or her, or with angst that some ominous process is brewing. It is remarkably common to have patients with the same problem say that they have seen many physicians over the years, that they have been through an extraordinary number of investiga-




Fig. 1. The dots represent upper and lower back areas where trigger points commonly occur.



Fig. 2. The dots represent the same common trigger points that are shown in Figure 1 as they are identified clinically. The points are bilateral but, for clarity, are shown here unilaterally.

tions and that they have often been prescribed protracted doses of narcotics. They are happy to leave the office pain-free with an exercise prescription in hand (or low dose amitriptyline at hs). A recurrence of symptoms requiring a repeat injection every 6–12 months is not uncommon. Once the diagnosis is made, a busy practitioner might refer a patient to a chiropractor, massage therapist or acupuncturist, etc., often with similarly good results.

PROCEDURE

The procedure is easy and only takes a few moments.

STEP 1

In our experience 0.25% bupivacaine 1–2 mL per trigger point is appropriate. The long-acting nature of this agent will prevent the local soreness that some patients experience from the process. One percent or 2% lidocaine can also be used.

STEP 2

The trigger point is localized with finger pressure —

it is often helpful to landmark the spot with the plastic needle cover to create a superficial “target” impression on the skin (Fig. 3, Fig. 4 and Fig. 5).



Fig. 3. The image shows how the trigger point is found, by gentle palpation and increased finger pressure, which causes a local and radiating reproduction of the pain that is consistent with the symptoms.



Fig. 4. The image shows how the skin is stretched between 2 fingers to lessen the pain of injection and immobilize the underlying muscle knot.



Fig. 5. The most tender spot is localized accurately using the needle cover and giving the patient choices until the sorest spot is identified and marked with pressure. This gives a “bullseye” to inject.

STEP 3

After an alcohol swipe, the 25-gauge needle is inserted smoothly to the clinical depth; usually 1 cm into muscle or interspinous ligament (Fig. 6 and Fig. 7). The amount of overlying adipose tissue will




Fig. 6. The image shows how the technique in Figure 5 is followed by an alcohol swipe, using clean technique.




Fig. 7. The needle is uncovered and placed smartly through the skin, entering to an approximate muscle depth of 1 cm. The physician will eventually develop a feel for when he or she is entering the affected muscle. The injection is made slowly and is accompanied by an anticipated initial increase in the pain along the particular radicular pattern identified by the patient. If there is no temporary worsening of the pain, the needle has likely missed the mark and may need to be repositioned.

determine total needle depth; the physician will feel the increase in resistance upon entering the muscle. At the moment of injection the patient will often identify an intense reproduction of their presenting symptoms and, importantly, in the same radiating pattern. This is a good sign and usually correlates with positive outcome.

CONCLUSION

Mastering the simple trigger point injection allows the practitioner to identify and treat pains that do not fit traditional patterns. It sometimes allows for immediate resolution of the pain without the need for further investigation. Follow-up with the patient will allow us to identify successful interventions that may be repeated if the trigger point becomes active in the future. This is a safe and simple procedure that we may often overlook, particularly in our more challenging patients.

Competing interests: None declared.

REFERENCES

1. Hong CZ, Hsueh TC. Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. *Arch Phys Med Rehabil* 1996;77:1161-6.
2. Rudin NJ. Evaluation of treatments for myofascial pain syndrome and fibromyalgia. *Curr Pain Headache Rep* 2003;7:433-42.
3. Han S, Harrison P. Myofascial pain syndrome and trigger-point management. *Reg Anesth* 1997;22:89-101.
4. Baldry P. Management of myofascial trigger point pain. *Acupunct Med* 2002;20:2-10.
5. Schneider MJ. Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. *J Manipulative Physiol Ther* 1995;18:398-406.
6. van Tulder MW, Cherkin DC, Berman B, et al. The effectiveness of acupuncture in the management of acute and chronic low back pain. A systematic review within the framework of the Cochrane Collaboration Back Review Group. *Spine* 1999;24:1113-33.
7. Iwama H, Akama Y. The superiority of water-diluted 0.25% to neat 1% lidocaine for trigger point injections in myofascial pain syndrome: a prospective, randomized, double blinded trial. *Anesth Analg* 2000;91:408-9.
8. Byrn C, Olsson I, Falkheden L, et al. Subcutaneous sterile water injections for chronic neck and shoulder pain following whiplash injuries. *Lancet* 1993;341:449-52.
9. Wreje U, Brorsson B. A multicenter randomized controlled trial of injections of sterile water/saline for chronic myofascial pain syndromes. *Pain* 1995;61:441-4.
10. Fine PG, Milano R, Hare BD. The effects of myofascial trigger point injections are naloxone reversible. *Pain* 1988;32:15-20.
11. Garvey TA, Marks MR, Wiesel SW. A prospective randomized double-blinded evaluation of trigger-point therapy for low-back pain. *Spine* 1989;14:962-4.
12. Davies C, Davies A. *The trigger point therapy workbook*. 2nd ed. Oakland (CA): New Harbinger Publications; 2004.
13. Travell JG, Simons DG. *Myofascial pain and dysfunction: the trigger point manual*. Vol 1 and 2. Baltimore (MD): Lippincott, Williams and Wilkins; 1992.

SERVICE INFORMATION

Society of Rural Physicians of Canada (SRPC) members: Subscription price included in membership fee.

Nonmembers (2007 rates): *Individuals:* Canada, \$72 (single copy, \$30); USA and elsewhere, US\$85. *Institutions:* Canada, \$116 (single copy, \$30); USA and elsewhere, US\$126 (single copy, US\$30). *Students* \$35 Canadian/US\$. Please contact the CMA Member Service Centre (see next paragraph) for other information. These rates include surface postage. Canadian subscribers please add 6% GST/14% HST (NS, NB, NL) as applicable.

All subscriptions are payable in advance. Payment should be made to the Canadian Medical Association (CMA) in the funds specified. MasterCard, VISA and American Express are accepted. Orders or requests for information should be addressed to: *CJRM*, CMA Member Service Centre, 1867 Alta Vista Dr., Ottawa ON K1G 3Y6; 888 855-2555 x2307 (Canada/US) or 613 731-8610 x2307; fax 613 236-8864; cmamsc@cma.ca

Missing issues: Claims for missing issues must be made within 3 months of publication date (subject to availability).

Change of address: Send one month before effective date to the CMA Member Service Centre (see above) for Canadian addresses, or to International Media Services of New York, 100 Walnut St., #3, PO Box 1518, Champlain NY 12919-1518 (US and elsewhere).

Reprints: Bulk reprints of *CJRM* articles are available in minimum quantities of 50. For information please contact the reprint coordinator, Janis Murrey, 800 663-7336 or 613 731-8610 x2110; fax 613 565-7704; permissions@cma.ca.

Copyright and Permissions: Copyright for all material is held by the SRPC or its licensors, unless otherwise indicated. You may reproduce or otherwise use material from this journal only in accordance with Canadian copyright law and provided that credit is given to the original source. In the case of photocopying or other reprographic copying, please contact the Canadian Copyright Licensing Agency (Access Copyright): 800 893-5777; www.accesscopyright.ca. For any other use, including republishing, redistribution, storage in a retrieval system or transmission in any form or by any means, please contact Permissions Coordinator, CMA Publications, 1867 Alta Vista Dr., Ottawa ON K1G 3Y6; fax 613 565-7704; permissions@cma.ca

Indexing and Abstracting: *CJRM* is available through the following services: MEDLINE/*Index Medicus*, Ovid Technologies, EbscoHost EJS, ProQuest Information and Learning Company, CAB Abstracts, Global Health and *Ubblich's International Periodicals Directory*. All articles published in *CJRM* are available free at the time of publication at www.cma.ca/cjrm.

RuralMed: Information on RuralMed (the SRPC Listserv) is available online at www.srpc.ca.

Advertising: Classified ads: Contact Bev Kirkpatrick or Deborah Rodd, *CJRM*, 1867 Alta Vista Dr., Ottawa ON K1G 3Y6; 800 663-7336 or 613 733-8610 x2127/2314, fax 613 565-7488, advertising@cma.ca. See Classified Advertising section of *CJRM* for information on rates. **Display ads:** Contact Deborah Woodman (see preceding information); x2159.